Holger Behrsing,1 Mario Aragon,1 Jason Adamson,2 Devin Sheehan,1 Marianna Gaca,2 Rodger Curren,1 and Erin Hill1
1Respiratory Toxicology, Institute for In Vitro Sciences, Inc., Gaithersburg, Maryland.
2R&D, British American Tobacco, Southampton, United Kingdom.
The study shows an assessment of VC1 aerosol generation that was conducted by measuring puff-by-puff in vitro nicotine concentration of 3R4F cigarettes (ISO and HCI regimes), e-cigarette (CRM81 puffing profile), and THP (HCIm regime). The aerosols were applied to in vitro or ex vivo cellular and tissue systems that model the respiratory tract, such as reconstructed human airways (RHuA), which are grown at the air–liquid interface (ALI). Additionally a comparison between the Vitrocell VC1 (U.S. Laboratory) and the VC10 (UK Laboratory) Smoking Robot was done.